Infectious Disease

Review 9 new FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for migraine, CSU, RSV, and more.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.

The now 7-member ACIP will discuss dated issues including thimerosal in flu vaccine and MMR-related febrile seizures but not vaccines against cervical cancer and pneumonia.

The only pre-exposure prophylaxis approved for twice-a-year dosing, lenacapavir "could be the transformative PrEP option we’ve been waiting for," one expert said.

The CDC recommendation pertains to all international travel, regardless of destination, as a result of rising case numbers in the US.

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.

Cases of whooping cough in the US more than doubled in 2024, and 2 infants have died from the infection. Here is background on the infection and vaccine.

While 20% of US adults choose not to wash their hands at appropriate times, nearly half admitted to forgetting to do it, according to a new national survey.

Measles, declared eradicated in the US 25years ago, has infected 900 Americans and is responsible for 3 deaths of children younger than age 5. How did we get here?

Your daily dose of the clinical news you may have missed.

At current vaccination rates, measles could become endemic in the US again within 21 years; the threat extends to rubella, polio, and diphtheria, the study found.

Misinformation about measles and the MMR vaccine has reached the majority of US adults and parents; most believe the vaccine is safe but many are still unconvinced.

Data from the EAGLE-1 study found gepotidacin to be noninferior to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhea.

AAAAI 2025: RSV vaccine and immunoprophylaxis uptake remained low in 2024 across infants, pregnant individuals, and older adults.

As the US measles outbreak tops 600 cases, Texas reported a second child's death in a young girl who was unvaccinated and had no underlying health conditions.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.

The Women’s Sexual Health Test (Visby Medical) delivers results in approximately 30 minutes using a vaginal swab.

New research shows that treating both men and women with topical and oral antibiotics lowers the odds of bacterial vaginosis recurrence by more than half.

The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.

Gepotidacin is the first new oral antibiotic for uncomplicated urinary tract infections in 30 years, offering an alternative amid rising antibiotic resistance.

Researchers recommend expanding antimicrobial stewardship efforts to better track and reduce unnecessary antibiotic use.

CROI 2025: Researchers reported that a universal syphilis screening program identified more cases than programs targeting specific patient populations.

CROI 2025: Increased HPV vaccine coverage could reduce HIV cases by thousands, according to a new study.